Spexis and SPRIM Global Investments (SGI) announce plans for clinical trial partnership to fund up to half of the projected Phase 3 clinical development costs of ColiFin®

Written by Andreas Villaester on 8th February 2023. Posted in Client News.

• Previous
• Next